Keyphrases
Immune Checkpoint Inhibitors
100%
PET Imaging
100%
Programmed Death-ligand 1 (PD-L1)
100%
Tracer Uptake
100%
Tumor Response
100%
Metastatic Melanoma
100%
Brain Metastases
100%
Tumor-like Lesions
75%
Lesion Diameter
75%
PET Scan
50%
Positron Emission Tomography-computed Tomography (PET-CT)
50%
Response Evaluation
50%
Local Treatment
25%
Lung
25%
Response Predictors
25%
Thyroiditis
25%
Liver
25%
Spleen
25%
Kidney
25%
Metastasis
25%
Colitis
25%
Area under the Curve
25%
Receiver Operating Characteristic Analysis
25%
Whole-body
25%
Computed Tomography
25%
Non-invasive Imaging
25%
Metastatic Lesions
25%
Bone Marrow
25%
Abdomen
25%
Healthy Tissue
25%
Therapy Response
25%
Common Terminology Criteria for Adverse Events (CTCAE)
25%
Brain MRI
25%
Induced Toxicity
25%
Tumor Location
25%
Lesion Volume
25%
Melanoma Patients
25%
Blood Pool
25%
Baseline Scan
25%
Response Evaluation Criteria in Solid Tumors (RECIST)
25%
Tissue Lesion
25%
Organ Lesion
25%
CT Thorax
25%
Heterogeneous Uptake
25%
PD-L1 Expression
25%
Immune Checkpoint Inhibitor Therapy
25%
Immune Checkpoint Inhibitor Treatment
25%
Medicine and Dentistry
Fluorine-18
100%
Positron Emission Tomography
100%
Brain Metastasis
100%
Programmed Death-Ligand 1
100%
Metastatic Melanoma
100%
Immune Checkpoint Inhibitor
100%
Neoplasm
72%
Radioactive Tracer
36%
Positron Emission Tomography
18%
Positron Emission Tomography-Computed Tomography
18%
Treatment Response
9%
Chest
9%
Metastatic Carcinoma
9%
Nodular Melanoma
9%
Adverse Event
9%
Colitis
9%
Local Therapy
9%
Thyroiditis
9%
Magnetic Resonance Imaging of Brain
9%
Immunology and Microbiology
Positron Emission Tomography
100%
Programmed Death-Ligand 1
100%
Positron Emission Tomography-Computed Tomography
66%
Nomenclature
33%
Magnetic Resonance Imaging
33%
Colitis
33%
Thyroiditis
33%
Lesion Volume
33%